concentrations have been consistently associated with excess mortality in epidemiological studies, but this association could be due to confounding by health impairments associated with low 25(OH)D levels. An association of vitamin D-related genetic variants with all-cause mortality could strengthen the claims of causality, because this association is assumed to be unaffected by confounding.
metabolically active vitamin D [1, 25(OH) 2 D] that binds to the ubiquitously expressed vitamin D receptor (VDR), thereby exerting diverse biological functions (3) . Mechanisms have been proposed to explain possible preventive effects of the active vitamin D metabolite on a variety of diseases, including cardiovascular disease (CVD) (4), cancer (5) , and respiratory infections (6) .
Various studies have identified single nucleotide polymorphisms (SNPs) that were associated with 25(OH)D serum concentrations. The advantage of these SNPs is that they do not depend on changes in sunlight exposure, lifestyle, food intake, and supplement use. Thus, an association between vitamin D-related SNPs and all-cause mortality could strengthen the claims of causality, because this association is assumed to be unaffected by confounding (7) . A few studies have already evaluated associations of these SNPs with mortality, but overall, their findings have been inconsistent, possibly due to the genetic variability in the populations being studied (8) (9) (10) . With regard to VDR SNPs, there are a few studies, but their findings are also inconclusive (11) (12) (13) .
To shed some light on the influence of genetic variants in the association of low vitamin D status with mortality, we assessed the association of SNPs in vitamin D pathway genes with mortality in the Epidemiological Study on Chances for Prevention, Early Detection, and Optimized THERapy of Chronic Diseases at Old Age [Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der alteren Bevölkerung (German)], which included a large cohort of German older adults. In particular, we aimed to distinguish the contribution made by genetics and the environment to the association of 25(OH)D with mortality.
Materials and Methods

Study population
The ESTHER study has been described in detail in earlier publications (14) . Briefly, it is an ongoing population-based cohort study being conducted in the federal state of Saarland (Germany) that focuses on improving prevention, early detection, and treatment of chronic diseases among older adults. Men and women 50 to 75 years of age were recruited from 2000 to 2002 by their general practitioners during a regular health check-up. Baseline data collection included a patient and general practitioner questionnaire, and blood samples were taken. These were centrifuged, delivered to the study center, and stored at 280°C until measurement.
The distribution of sociodemographic characteristics, prevalent diseases, and major risk factors in the ESTHER study are comparable to those in the German National Health Survey, which was conducted in a representative sample of the German population in 1998 (15) . The ESTHER study was approved by the Ethics Committees of both the Medical Faculty of the University of Heidelberg and the Medical Association of Saarland, and is being conducted in accordance with the Declaration of Helsinki.
25(OH)D measurement
Baseline circulating 25(OH)D serum concentration was first measured in women in the central laboratory of the University Hospital of Heidelberg with immunoassay (IA) as part of a project on women's health in 2006. Additional funding was obtained in 2009 to measure baseline 25(OH)D concentration in men as well. The IA method that was initially used for women was no longer available by that time; therefore, a different IA was used. Both measurement methods with their within-and between-assay coefficients and lower limits of detection have been comprehensively described elsewhere (16, 17) . Both IAs were standardized with liquid chromatography-tandem mass spectrometry, which is commonly considered the most reliable 25(OH)D measurement method (18) , in a random subsample of 97 men and 97 women (16, 17) .
Genotyping
DNA samples were extracted from baseline full blood samples. In the context of an international collaboration, 4 SNPs located in or around vitamin D pathway genes were successfully measured: rs3755967 (C/T) in the GC gene, which encodes the vitamin D binding protein, rs11603330 (A/C) in the DHCR7 gene, which encodes the 7-dehydroxcholesterol reductase, a key enzyme in the regulation of cholesterol and provitamin D levels, rs12794714 (G/A) in the CYP2R1 gene, which encodes the main vitamin D 25-hydroxylase, and rs17216707 (T/C) in the CYP24A1 gene, which encodes the vitamin D 24-hydroxylase enzyme, which is responsible for 25(OH)D and 1,25(OH) 2 D degradation. Details of the genotyping methods used have been reported elsewhere (19) . In addition, 2 SNPs in the VDR gene, rs2239179 (T/C) and rs7968585 (T/C), were later measured using the TaqMan assay (Applied Biosystems, Foster City, CA), with the purpose of replicating the findings from a previous study (12) . All 6 SNPs were in Hardy-Weinberg equilibrium, and no substantial linkage disequilibrium between SNPs was observed.
End point ascertainment
Follow-up for mortality was performed from baseline until 31 March 2013, by querying the registration offices for the participants' vital status. In case of death, death certificates were requested from local health authorities. Secondary mortality end points were defined according to the International Classification of Diseases 10th Edition codes C00 to C97 (mortality from invasive cancers) and I00 to I99 (cardiovascular mortality).
Statistical analyses
The ESTHER baseline sample size includes 9949 participants. After exclusion of participants without genotype data (n = 1531) or complete mortality follow-up (n = 2), the initial population for the present analyses was 8417 participants. In analyses with just 1 SNP, those with a missing genotype for that SNP were excluded. In analyses employing 25(OH)D data, those with a missing 25(OH)D concentration were excluded (n = 223). Finally, in analyses with confounder adjustment, those with missing values for the pertinent covariates were also excluded.
Multivariate linear regression was used to assess the association of SNPs with 25(OH)D concentration under an additive model, which assesses the effect of an increase in 1 minor allele. Multivariate logistic regression models, adjusted for age, sex, and BMI, were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of SNPs with risk of low vitamin D status, defined as a 25(OH)D concentration less than the lowest season-specific 33rd percentile (i.e., 33, 34, 43, and 41 nmol/L in winter, spring, summer, and autumn, respectively). Vitamin D status was considered to be normal if the 25(OH)D concentration was above the season-specific 33rd percentile. We decided to use season-specific cutoff points to define low vitamin D status, because this is the less biased method to account for the seasonal variability in vitamin D concentrations (20) . Nevertheless, we also defined low vitamin D status as below the World Health Organization clinical cutoff point for deficiency (50 nmol/L) (21), adjusted for season of blood draw in the model, and compared the results to those of the earlier method.
SNPs that were consistently significantly associated with 25(OH)D concentration in linear regression, and with risk of low vitamin D status in logistic regression, were combined into a genotype score summing the number of risk alleles associated with lower 25(OH)D concentration and hence determining the higher risk of low vitamin D status.
Cox proportional hazards models were used to derive hazard ratios (HRs) and 95% CIs for the association of SNPs with allcause, cardiovascular disease (CVD), and cancer mortality. HRs and 95% CIs were derived in a crude model, and in 3 more models with an increasing number of covariates. Model 1 was adjusted for sex and age. Model 2 was additionally adjusted for BMI, smoking status (never, former, or current), and physical activity (inactive, low, medium, or high). Model 3 further controlled for factors potentially influenced by vitamin D levels, i.e., CRP levels (continuous), personal history (yes, no) of CVD, hypertension, high cholesterol levels, diabetes, cancer, chronic kidney disease, and hip fractures.
Cox proportional hazards models were also used to assess the association of low vitamin D status (as defined earlier) with all-cause, CVD, and cancer mortality among those with "genetically low" vitamin D status, i.e., at least 1 minor allele associated with low 25(OH)D concentration, and among those with "otherwise low" vitamin D status, i.e., no minor allele associated with low 25(OH)D concentration. The reference group consisted of those with normal 25(OH)D concentrations and no minor alleles associated with low 25(OH)D concentration. Risk estimates were adjusted for sex, age, BMI, smoking status, physical activity, level of education (primary, secondary, university, or higher), regular multivitamin use (yes, no), C-reactive protein (CRP) levels (continuous), and personal history (yes, no) of CVD, hypertension, diabetes, cancer, and chronic kidney disease. All statistical tests were 2-sided, using an alpha level of 0.05. To correct for multiple testing, we used the Bonferroni method, which divides the 2-sided P value by a correction factor, in this case equal to the number of SNPs under analysis (n = 6). All analyses were conducted with SAS software, version 9.4 (SAS Institute, Cary, NC).
Results
Baseline characteristics of the participants according to vital status can be seen in Table 1 . At baseline, those who died were, in comparison with survivors, more often men, significantly older, more overweight, had higher CRP levels, were more often physically inactive, more often smokers, had a lower education, and were more likely to have suffered from CVD, cancer, diabetes, hypertension, chronic kidney disease, and hip fracture before entering the study. In addition, those who died, compared with those who survived, had lower 25(OH)D levels.
Overall, most of the SNPs were not associated with baseline characteristics (data not shown). There were 2 exceptions: for rs3755967 (GC), among those with at least 1 minor allele, more had suffered from hypercholesterolemia (n = 1720; 43%) than among those without a minor allele (n = 1769; 40%; P = 0.01); and for rs7968585 (VDR), those with at least 1 minor allele less often reported having a chronic kidney disease (n = 815; 15%) than those without a minor allele (n = 557; 19%; P , 0.01).
25(OH)D concentrations were available for 8194 study subjects with complete genotyping at all loci; of these, 2941 had low 25(OH)D concentrations ( Table 2 for 25(OH)D concentrations below the 33rd percentile (Supplemental Table 1 ). Different versions of the genotype score that additionally included rs12794714 (CYP2R1) and rs17216707 (CYP24A1) were associated with more moderate increases in risk of low vitamin D status [OR (95% CI) per minor allele, 1.13 (1.08 to 1.17) and 1.12 (1.08 to 1.16), respectively].
After up to 12 years of follow-up (mean, 11 years), a total of 1338 deaths from any cause were registered, of which 449 were a result of CVD and 500 a result of cancer. The associations of genotype score and SNPs with mortality end points are shown in Table 3 . Adjustment for covariates did not result in any relevant change in the risk estimates presented in Table 3 , and the SNPs were not associated with any other predictors of mortality; thus, the crude (unadjusted) results were considered as main results. The genotype score was inversely associated with all-cause mortality [HR (95% CI) per minor allele, 0.93 (0.88 to 0.99)] but not with CVD and cancer mortality. The association of "genetically low" and "otherwise low" 25(OH)D concentrations with mortality end points are shown in Table 4 . Compared with subjects with normal 25(OH)D levels and no minor alleles of either rs3755967 (GC) or rs11603330 (DHCR7), those with 25(OH)D concentrations below the 33rd percentile and at least 1 minor allele ["genetically low 25(OH)D"] had significantly increased all-cause mortality and, with the exception of rs11603330 (DHCR7), cancer mortality as well. However, for all-cause mortality, these associations were even stronger for participants with "otherwise low" 25(OH)D concentrations; for CVD, increased mortality was exclusively seen for participants with "otherwise low" 25(OH)D, but not for those with "genetically low" 25(OH)D concentrations.
Discussion
In this large population-based cohort study, we have found 2 SNPs located in the GC and DHCR7 genes of the vitamin D pathway to be related to lower 25(OH)D concentrations and higher risk of low vitamin D status. Low 25(OH)D levels were associated with increased allcause, CVD, and cancer mortality. However, SNPs were not associated with mortality end points. Furthermore, the increase in mortality was smaller among those with "genetically low" 25(OH)D concentrations than among those with "otherwise low" 25(OH)D concentrations.
Over the last 10 years, there have been many observational studies assessing the association of 25(OH)D concentrations with the risk of mortality (22) . Their a HRs and 95% CIs derived from Cox multivariate models did not significantly differ from those derived from the crude models; thus, the results shown correspond to the latter. b Genotype score was created by summing the number of minor alleles significantly associated with lower 25(OH)D concentration for those subjects without missing genotype for the SNPs rs3755967 (GC) and rs11603330 (DHCR7).
results have been summarized in a meta-analysis of available published aggregate data (1). More recently, this association has been verified in a large consortium of older adults from Europe and the United States for whom individual participant 25(OH)D and vital status data were available (23) . The findings of all these previous observational studies are very consistent in suggesting that low 25(OH)D concentration is a risk factor for mortality. Meta-analyses of high-quality cohort studies are considered to be near the top of the evidence-based medicine pyramid, second only to randomized controlled trials (RCTs) (24) . Still, for many critics, low vitamin D status is not regarded as a potential causal factor for mortality but rather a marker of poor health (2, 25, 26) . More recently, a systematic review and meta-analysis of RCTs has confirmed the findings from observational studies by showing how vitamin D supplementation reduces the risk of all-cause and cancer mortality (27) . Although these findings are promising, the limitations of these RCTs and, in particular, their limited external validity due to the highly selected populations, need to be kept in mind. In any case, there is also a substantial body of evidence from experimental studies that supports plausible biological mechanisms by which vitamin D could influence risk of death (22) . Epidemiological studies that assess associations of vitamin D-related SNPs with mortality may provide an alternative to RCTs, enabling confounding to be bypassed without the inherent problems of limited generalizability in RCTs. Random allocation of vitamin D-related SNPs occurs at gamete formation; thus, individuals' genotypes are independent of confounding factors. Mendelian randomization has been used to study the association of vitamin D with mortality in various study populations with diverse findings (8) (9) (10) 12) . Previous studies have focused on a variety of vitamin D pathway genes, such as GC (8, 9), DHCR7 (8-10), CYP2R1 (8-10), CYP24A1 (8), and VDR (12). Our study analyzed SNPs in all known, potentially relevant vitamin D pathway genes in relation to mortality end points. In most previous studies, no significant associations of SNPs with mortality were observed, but these studies may have been underpowered to detect weak associations of SNPs with mortality end points. A notable exception is a significantly larger pooled analysis of Danish cohort studies (10) , in which only variants in DHCR7 and CYP2R1 genes were assessed. Per every additional allele associated with lower 25(OH)D concentrations, the risk of all-cause and cancer mortality was slightly increased. In the population of this Danish study (10) , as in our study, no association of "genetically low" 25(OH)D concentrations with CVD mortality was observed. Furthermore, in a more recent analysis of the same study population, no association of genetically low 25(OH)D concentrations with ischemic heart disease or myocardial infarction risk was observed, thus suggesting that the association of circulating 25(OH)D concentration with CVD may be due to confounding or reverse causality (28) .
In our study we have shown that SNPs in vitamin D pathway genes were overall not associated with mortality Nevertheless, the differences in the risk estimates between "genetically low" and "otherwise low" 25(OH)D may be due to chance, given that the CIs for both estimates were mutually inclusive. Further studies are needed to confirm or reject these hypotheses. Our study has several advantages and limitations. The most important limitation was our sample size, which did not allow us to apply the Mendelian randomization approach and may have precluded us from observing small SNP effects. In addition, we could only assess the risk of mortality for 6 SNPs, whereas genome-wide association studies have identified larger number of SNPs influencing 25(OH)D concentrations (19, 29, 30) . However, previous studies have observed linkage disequilibrium between the polymorphisms in GC and CYP2R1 assessed in our study and other variants within the same genes (8) . Also, these polymorphisms have been significantly associated with 25(OH)D, a finding that enhances the external validity of the results for the selected SNPs. Little is understood about the functionality and potential pleiotropy of vitamin D pathway SNPs. Further research should aim to study the phenotype of the relevant enzymes according to genetic variation in the given genes. Finally, we cannot exclude the possibility of incomplete confounding adjustment for the association of low 25(OH)D with mortality end points due to incomplete information on vitamin D and calcium intake from diet and supplementation, as well as parathyroid hormone levels, all important variables that are associated with both 25(OH)D concentrations and with risk of death (27, 31, 32) .
Although our study was limited by the number of SNPs assessed, unlike previous studies, we covered all 5 relevant vitamin D pathway genes. In addition, our study benefited from its population-based and prospective design, the complete follow-up on mortality data, and, most importantly, the availability of standardized 25(OH)D measurements for all subjects.
In summary, in this large population-based cohort study of German older adults, we observed associations of vitamin D genetic variants with low vitamin D status but not with mortality end points. However, low 25(OH)D levels were associated with increased mortality, although this association was weaker among those with "genetically low" 25(OH)D concentrations than among those with "otherwise low" 25(OH)D concentrations, thus supporting the suggestion that the strong association of low vitamin D status with mortality may be at least partly due to other factors. Further observational studies are needed, preferably with more detailed genotyping of the different vitamin D pathway genes, and ideally within the context of large genetic epidemiology consortia.
